Results 181 to 190 of about 7,028 (198)

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet, The, 2021
Eric L Simpson, Aileen L Pangan, Diamant Thaçi   +2 more
exaly  

Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience

Clinical Gastroenterology and Hepatology, 2023
Nathaniel A Cohen, Sushila R Dalal
exaly  

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
Aileen L Pangan, In-Ho Song
exaly  

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
KRISTIAN Reich, Marjolein De Bruin-Weller, Thomas Bieber   +2 more
exaly  

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

New England Journal of Medicine, 2021
Iain B Mcinnes, Marina Magrey, Joseph F Merola   +2 more
exaly  

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Drug Design, Development and Therapy, 2022
Ferdinando D´Amico, Elisa Maria Ragaini, Laurent Peyrin-Biroulet   +2 more
exaly  

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

Journal of Clinical Pharmacology, 2020
Mohamed-Eslam F Mohamed, Denise Beck, Ahmed A Othman   +2 more
exaly  

Management of Axial Spondyloarthritis – Insights into Upadacitinib

Drug Design, Development and Therapy, 2022
J Braun, Uta Kiltz, Xenofon Baraliakos   +2 more
exaly  

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Clinical Pharmacology in Drug Development, 2019
Mohamed-Eslam F Mohamed, Jiewei Zeng, In-Ho Song   +2 more
exaly  

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

Journal of Clinical Pharmacology, 2019
Mohamed-Eslam F Mohamed, Tian Feng, Jaclyn K Anderson   +2 more
exaly